US companies hit hardest by fake medicines: EUIPO, OECD

Companies registered in the US are hit hardest by the trade in counterfeit medicines, which in 2016 reached $4.4 billion, according to a report from the European Union Intellectual Property Office (EUIPO).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Large-scale probe seizes 10.5m fake medicines

20 December 2022 Operation took place across Europe | Criminal networks are still exploiting opportunities offered by the COVID-19 pandemic.

Big Pharma

Fraudsters will invest heavily in fake COVID-19 vaccine: Europol

1 May 2020 Once a genuine vaccine against COVID-19 has been announced, counterfeiters and fraudsters are likely to invest heavily in offering ineffective counterfeit versions of the vaccine online, according to Europol.

Big Pharma

OECD and Europol issue COVID-19 counterfeits warning

22 April 2020 The COVID-19 pandemic is heightening the dangers posed by the global trade in counterfeit pharmaceutical products, according to the OECD and EUIPO.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

US companies hit hardest by fake medicines: EUIPO, OECD

More on this story

Editor's picks

Editor's picks

More features